Medical Aesthetic Products’ Manufacturer Croma-Pharma Launches “Croma is More” E-Learning Series for Health Care Professionals
Croma-Pharma GmbH (Croma) always strives to support physicians in their work in the best possible way. For this reason, the company has developed an interactive e-learning platform with continuing education offerings for physicians working in the field of minimally invasive aesthetic. In this way, Croma aims to help health care professionals achieve sustainable growth and success in their medical clinics/practices.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210422005727/en/
Social Media Training for Health Care Professionals Copyright: Croma-Pharma GmbH (Graphic: Business Wire)
Medical professionals can choose from a broad variety of different formats:
- Social Media & Online Marketing
- Facial Anatomy Workshops
- Aesthetic Startup Academy
- Aesthetic Excellence
A variety of topics is presented by Industry experts. All the content comes with lifetime access hence the health care professionals can learn on their own schedule and at their own pace.
A multi-professional panel of international practitioners and the latest evolution of learning methods guarantee a highly efficient transfer of skills and knowledge in an interactive and individualized way.
More information is found via https://learn.cromaismore.com
About Croma
Founded in 1976, Croma-Pharma GmbH (Croma) is an Austrian family-owned company that specializes in the industrial production of hyaluronic acid syringes for the fields of medical aesthetics, ophthalmology and orthopaedics. Croma currently runs 12 international sales companies and distributes its products in more than 70 countries. Within its global sales network, Croma focuses with own branded products on minimally invasive aesthetic medicine. Besides a broad range of HA fillers from the own production site, Croma markets PDO lifting threads, a Platelet Rich Plasma (PRP) system and high quality skincare technologies in its core strategic markets.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210422005727/en/
Contact information
CROMA-PHARMA GmbH
Stefanie Höhn
Global Director Communications
Cromazeile 2
A-2100 Leobendorf
Tel.: +43 676 846868 190
Mail: stefanie.hoehn@croma.at
Web: www.croma.at
CROMA-PHARMA GmbH
Simone Turek
External Communications
Cromazeile 2
A-2100 Leobendorf
Tel.: +43 676 846868 654
Mail: simone.turek@croma.at
Web: www.croma.at
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Altasciences Initiates Phase I Study in Healthy Normal Subjects for ST-2427, a Non-Opioid Analgesic for Acute Pain13.5.2021 18:31:00 CEST | Press release
Altasciences is pleased to support SiteOne Therapeutics with a Phase I, randomized, double-blind, placebo-controlled study in healthy adults to evaluate the safety, tolerability, and pharmacokinetics of ST-2427. ST-2427 is a highly selective inhibitor of NaV1.7 for the management of moderate-to-severe pain; by selectively targeting NaV1.7, ST-2427 aims to stop the electrical signals responsible for pain before they reach the central nervous system. Amy Denvir, General Manager of Altasciences’ Kansas City clinical site, says, “We are proud to partner with SiteOne Therapeutics and help move this important therapeutic into clinical trials. Helping bring to market a new approach that may provide a non-opioid option to treat moderate- to-severe pain is an exciting prospect, and we look forward to delivering this ground-breaking research.” Click here to read the SiteOne press release. Altasciences has designed and conducted hundreds of first-in-human trials by offering comprehensive, full se
NameExperts.com Announces the Exclusive Category-Defining Website Watches.com for Acquisition13.5.2021 17:30:00 CEST | Press release
Name Experts LLC., a boutique domain name and website brokerage firm, announces the exclusive offering of Watches.com. Watches.com is a complete turn-key Website offering an Ecommerce end-to-end shopping experience with a lucrative B-to-C model. Watches.com has a significant organic profile, generating substantial traffic and revenues with a history of stable organic traffic. Watches.com currently ranks in position # 1 for the term “Watches” on Google. According to Domain expert Joe Uddeme, “Watches.com represents an opportunity to capitalize on the scale available with such a globally positioned category-defining URL. This is the pinnacle of beachfront real estate.” A unique opportunity exists to scale the property with additional lines of mainstream Watch brands and leveraging, additional industry-wide relationships. Watches.com is the singular source for unusual modern watches from around the world. Terms of Sale: Website Acquisition to include all content, intellectual property, so
Lunaphore Announces Appointment of Matthias Weber, Former President of Leica Biosystems, to Board of Directors13.5.2021 17:00:00 CEST | Press release
Lunaphore Technologies SA, a Swiss life-sciences company developing innovative next-generation equipment for cancer research, announces the appointment of Matthias Weber, former President of Leica Biosystems, to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210513005627/en/ Matthias Weber - The new member of Lunaphore’s Board of Directors (Photo: Business Wire) Mr. Weber brings extensive experience in the cancer diagnostics and immunohistochemistry fields, marked by excellence in a range of diverse strategic roles including Product Management, R&D, Operations, Sales & Marketing, and most notably as President at Leica Biosystems, a position which he held between 2012 and 2019. Mr. Weber commented: “I am delighted to join Lunaphore’s Board and to be part of a great team of innovators that will change the future of Immunohistochemistry (IHC) and Cancer Diagnostics”, and he added: “especially in the fiel
SentinelOne Receives Highest Score for Type B Use Case in the Gartner 2021 Critical Capabilities for Endpoint Protection Platforms13.5.2021 16:00:00 CEST | Press release
SentinelOne, the autonomous cybersecurity platform company, today announced that Gartner has positioned SentinelOne with the highest score in use case Type B in Gartner’s 2021 Critical Capabilities for Endpoint Protection Platforms report1. SentinelOne received the highest score for all three customer types out of 19 vendors. Gartner says, “Type B organizations aim to stay relatively current on technology without getting too far ahead or behind their competition.” “We believe receiving the highest product score among organizations prioritizing overall value in the 2021 Critical Capabilities for Endpoint Protection Platforms validates our vision and execution in delivering an AI-powered platform purpose built for the demands of the mainstream enterprise market,” said Raj Rajamani, Chief Product Officer, SentinelOne. “These organizations represent the largest market segment out of Gartner’s use cases and prioritize technology deployments that improve their organization’s productivity, pr
Wipro Has Earned the Microsoft Windows Virtual Desktop Advanced Specialization13.5.2021 15:12:00 CEST | Press release
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today said it has earned the Microsoft Windows Virtual Desktop advanced specialization, a validation of a partner’s deep knowledge, extensive experience and expertise in deploying, scaling and securing virtual desktop infrastructure on Azure. Only partners that meet stringent criteria around customer success and staff skilling, as well as pass a third-party audit of their Windows Virtual Desktop technical practices are able to earn the Microsoft Windows Virtual Desktop advanced specialization. Supporting secure remote work for employees is more critical than ever. Windows Virtual Desktop is a Microsoft solution that seamlessly integrates with other Microsoft products and allows customers to implement virtual desktops in a scalable, secure, and cost-effective way. Partners with validated capabilities in implementing Windows Virtual Desktop can he
Schlumberger Appoints Dr. Katharina Beumelburg as Chief Strategy and Sustainability Officer13.5.2021 15:00:00 CEST | Press release
Schlumberger announced today the appointment of Dr. Katharina Beumelburg to the position of Chief Strategy and Sustainability Officer, Schlumberger Limited, reporting to Olivier Le Peuch, Chief Executive Officer. The appointment is effective Monday, May 17. As a member of the executive team, Dr. Beumelburg will oversee corporate strategy, sustainability, marketing and communications activities across the Company. Dr. Beumelburg joins Schlumberger from a global technology company, Siemens, where she has held various leadership positions including strategy development incorporating sustainability; management consulting; business excellence; and operations management. In her most recent position, she led the global Transmission Services business. “I am delighted to welcome Katharina to the Schlumberger team at a pivotal time for the company, the energy industry and our planet. Sustainability is increasingly core to our performance strategy, through which we will realize our vision,” said
Ferring and Rebiotix to Present Landmark Data for Investigational Microbiota-based Live Biotherapeutic RBX2660 at Digestive Disease Week ® (DDW) 202113.5.2021 14:00:00 CEST | Press release
Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced that Phase 3 data evaluating its investigational microbiota-based live biotherapeutic RBX2660 for reduction of recurrent Clostridioides difficile(C. difficile) infection will be presented as part of an invited talk at Digestive Disease Week® (DDW) 2021. The congress will take place virtually from May 21-23, 2021. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210513005129/en/ “These data are the pinnacle of a decade of ground-breaking research and development, driven by the goal of helping those who are experiencing the debilitating effects of recurrent C. difficile infection,” said Lee Jones, Founder, President and Chief Executive Officer of Rebiotix, a Ferring Company. “We’re striving to deliver innovative therapeutics to help people live better lives, and are proud to be pioneering a new category of scientifically-validated, microbiome-based therapeu